These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 20227055)
1. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Herzog TJ; Krivak TC; Fader AN; Coleman RL Am J Obstet Gynecol; 2010 Jul; 203(1):68.e1-6. PubMed ID: 20227055 [TBL] [Abstract][Full Text] [Related]
2. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801 [TBL] [Abstract][Full Text] [Related]
3. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812 [TBL] [Abstract][Full Text] [Related]
4. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475 [TBL] [Abstract][Full Text] [Related]
5. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S; Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660 [TBL] [Abstract][Full Text] [Related]
6. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821 [TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
10. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gronlund B; Høgdall C; Hansen HH; Engelholm SA Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424 [TBL] [Abstract][Full Text] [Related]
11. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Markman M; Federico M; Liu PY; Hannigan E; Alberts D Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148 [TBL] [Abstract][Full Text] [Related]
12. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
14. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895 [TBL] [Abstract][Full Text] [Related]
15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107 [TBL] [Abstract][Full Text] [Related]
16. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related]
17. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987 [TBL] [Abstract][Full Text] [Related]
18. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452 [TBL] [Abstract][Full Text] [Related]
19. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320 [TBL] [Abstract][Full Text] [Related]